Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 368

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 368
---
 9,483  
     9,623 
  
    Research and development 
     33,166  
     20,273 
  
    Total operating expenses 
     42,649  
     29,896 

    LOSS FROM OPERATIONS 
     (42,635) 
     (29,741)

    OTHER INCOME (EXPENSE), NET 

    Other income (expense), net 
     553  
     (267)
  
    Total other income (expense), net 
     553  
     (267)

    NET LOSS 
    $(42,082) 
    $(30,008)

    Net loss per common share – basic and diluted 
    $(2.11) 
    $(1.67)

    Weighted average number of common shares outstanding – basic and diluted 
     19,944,304  
     17,980,791 

    COMPREHENSIVE LOSS 

    Net loss 
    $(42,082) 
    $(30,008)
  
    Other comprehensive income (loss) – foreign currency translation 
     224  
     (100)
  
    Total comprehensive loss 
    $(41,858) 
    $(30,108)

See accompanying notes to these consolidated financial
statements. 

F-4

INMUNE BIO INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’
EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In thousands, except share amounts)

    Common Stock  
    Additional Paid-In  
    Accumulated Other Comprehensive  
    Accumulated  
    Total Stockholders’ 

    Shares  
    Amount  
    Capital  
    Income (loss)  
    Deficit  
    Equity 
  
    Balance as of January 1, 2023 
     17,945,995  
    $18  
    $151,799  
    $(699) 
    $(91,014) 
    $60,104 
  
    Issuance of common stock for cash, net 
     75,697  
     -  
     775  
     -  
     -  
     775 
  
    Reclassification to redeemable common stock 
     (75,697) 
     -  
     (799)